Darzalex-话题@MedSci - 梅斯（MedSci）

#Darzalex#

18篇内容 | 1203人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1441422, encodeId=3db41441422b1, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性, objectType=article, longId=200589, objectId=14462005895e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14462005895e, replyNumber=0, likeNumber=69, createdTime=2020-09-13, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14462005895e, moduleTitle=强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=14462005895e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441421, encodeId=a5341441421c0, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤, objectType=article, longId=199783, objectId=eb8f199e83c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb8f199e83c9, replyNumber=0, likeNumber=95, createdTime=2020-08-23, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb8f199e83c9, moduleTitle=FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=eb8f199e83c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441420, encodeId=3a5814414201a, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤, objectType=article, longId=193523, objectId=093019352369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=093019352369, replyNumber=0, likeNumber=94, createdTime=2020-05-06, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=093019352369, moduleTitle=FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=093019352369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441419, encodeId=f616144141945, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤, objectType=article, longId=188065, objectId=7e7c18806539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e7c18806539, replyNumber=0, likeNumber=60, createdTime=2020-02-16, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e7c18806539, moduleTitle=强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7e7c18806539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441418, encodeId=ba821441418e9, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS, objectType=article, longId=184567, objectId=14fb18456e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fb18456e61, replyNumber=0, likeNumber=69, createdTime=2019-12-13, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fb18456e61, moduleTitle=DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=14fb18456e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=加拿大卫生部批准DARZALEX与来那度胺和地塞米松联合用于不适合移植的初治多发性骨髓瘤患者, objectType=article, longId=182203, objectId=0a4818220319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a4818220319, replyNumber=0, likeNumber=75, createdTime=2019-11-02, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a4818220319, moduleTitle=加拿大卫生部批准DARZALEX与来那度胺和地塞米松联合用于不适合移植的初治多发性骨髓瘤患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0a4818220319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441416, encodeId=ef0d1441416b3, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, objectType=article, longId=180138, objectId=16d3180138ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d3180138ee, replyNumber=0, likeNumber=87, createdTime=2019-09-29, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d3180138ee, moduleTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=16d3180138ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441415, encodeId=80981441415ee, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点, objectType=article, longId=179450, objectId=b45b1e9450d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45b1e9450d9, replyNumber=0, likeNumber=76, createdTime=2019-09-16, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45b1e9450d9, moduleTitle=多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b45b1e9450d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441414, encodeId=c7df144141420, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤, objectType=article, longId=175459, objectId=e3f31e5459bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3f31e5459bb, replyNumber=0, likeNumber=76, createdTime=2019-07-16, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3f31e5459bb, moduleTitle=强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e3f31e5459bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441413, encodeId=ea7a144141365, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案, objectType=article, longId=175081, objectId=1ce51e50810d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ce51e50810d, replyNumber=0, likeNumber=70, createdTime=2019-07-11, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ce51e50810d, moduleTitle=苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1ce51e50810d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441412, encodeId=90d11441412c8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人, objectType=article, longId=167615, objectId=3d4d16e61584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d4d16e61584, replyNumber=0, likeNumber=97, createdTime=2019-06-05, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d4d16e61584, moduleTitle=2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3d4d16e61584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441411, encodeId=29f3144141155, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率, objectType=article, longId=155285, objectId=2ea6155285c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ea6155285c7, replyNumber=0, likeNumber=85, createdTime=2018-12-08, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ea6155285c7, moduleTitle=2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2ea6155285c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441410, encodeId=f4b31441410fa, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=NICE拒绝Darzalex组合用于多发性骨髓瘤的前治疗, objectType=article, longId=144490, objectId=39ef144490b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39ef144490b3, replyNumber=0, likeNumber=67, createdTime=2018-07-17, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39ef144490b3, moduleTitle=NICE拒绝Darzalex组合用于多发性骨髓瘤的前治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=39ef144490b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441409, encodeId=068a1441409b4, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=强生公司将停止Darzalex与抗PD-（L）1疗法联用的研究, objectType=article, longId=139371, objectId=36491393e183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36491393e183, replyNumber=0, likeNumber=70, createdTime=2018-05-30, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36491393e183, moduleTitle=强生公司将停止Darzalex与抗PD-（L）1疗法联用的研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=36491393e183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441408, encodeId=1f541441408ab, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤, objectType=article, longId=86946, objectId=6e9a869465e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e9a869465e, replyNumber=0, likeNumber=76, createdTime=2017-01-09, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e9a869465e, moduleTitle=强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6e9a869465e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441407, encodeId=4269144140ea2, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗, objectType=article, longId=75557, objectId=f64ae5557dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f64ae5557dd, replyNumber=0, likeNumber=67, createdTime=2016-08-22, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f64ae5557dd, moduleTitle=强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f64ae5557dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441406, encodeId=88981441406c7, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=强生/Genmab联手拿下Darzalex突破性疗法地位进军二线用药市场, objectType=article, longId=73919, objectId=9afae391959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9afae391959, replyNumber=0, likeNumber=80, createdTime=2016-07-29, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9afae391959, moduleTitle=强生/Genmab联手拿下Darzalex突破性疗法地位进军二线用药市场, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9afae391959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441405, encodeId=b1731441405f9, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, objectTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, objectType=article, longId=70647, objectId=2a45e0647b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a45e0647b2, replyNumber=0, likeNumber=86, createdTime=2016-06-15, rootId=0, userName=12498b37m73暂无昵称, userId=dad84828862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a45e0647b2, moduleTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2a45e0647b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Darzalex

2020-05-29

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性

2020-09-13

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤

2020-08-23

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤

2020-05-06

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤

2020-02-16

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS

2019-12-13

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

加拿大卫生部批准DARZALEX与来那度胺和地塞米松联合用于不适合移植的初治多发性骨髓瘤患者

2019-11-02

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤

2019-09-29

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点

2019-09-16

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤

2019-07-16

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案

2019-07-11

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人

2019-06-05

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率

2018-12-08

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

NICE拒绝Darzalex组合用于多发性骨髓瘤的前治疗

2018-07-17

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

强生公司将停止Darzalex与抗PD-（L）1疗法联用的研究

2018-05-30

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤

2017-01-09

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗

2016-08-22

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

强生/Genmab联手拿下Darzalex突破性疗法地位进军二线用药市场

2016-07-29

12498b37m73暂无昵称 (审核中...)

前往app查看评论内容

#Darzalex#

EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期

2016-06-15

科室
- - 订阅+
  - 更多科室
工具
服务